Canada markets closed

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7900+0.0100 (+0.56%)
At close: 04:00PM EDT
1.7600 -0.03 (-1.68%)
After hours: 07:57PM EDT
Sign in to post a message.
  • R
    Going to distribute 65 Million from asset sales to the SHAREHOLDERS!! HHMMM, maybe 2.00/share? Load Up ASAP!!!
  • B
    Barney Frank
    I’m uncertain as to why any company would do this? However, I’ll cash the check and keep my shares. Nothing to lose after that!
  • M
    Any guesses to the size of the special dividend? I’ll go with $1.90.
  • r
    Awesome news. Talk about shareholder friendly.
  • s
    Does someone know: What happened last may 20th when stock jumped a lot ? was it reverse split ? or ?
  • M
    Great looking chart, its up from here...Lets break the 2,- and go.up from there.
  • c
    Mìnimal resistance above $1.52. Any good news should send it flying. Best close since the Vertex news.
  • c
    Do not sell this before the Bluebird decision.
  • s
    Do you guys follow ( It seems way better than all the spam on the CBIO board - The alerts have been great!
  • c
    Sold at 1.84 around 10AM. Ran out of gas in that area. Gonna trade it. Looking for 1.60s
  • J
    1 yr target has been hiked to $15.50 i got in @1.28 good day today. Can't wait for news from the FDA to see if they grant a priority review voucher to a sponsor that received a product approval for a rare pediatric disease 🙏🙏🙏🤞🤞🤞
  • c
    I would expect a major move up today with a very strong close. Otherwise, I am off the mark on this.
  • c
    Lotta companies could buy this for $150M which includes $90M cash. Vertex interest has established their credibility. I see $5 in the near future.
  • c
    I would be watching for this next. This was second item of discussion in quarterly summary. Hopefully, they could monetize this voucher.

    "Under the FDA’s rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor that received product approval for a rare pediatric disease."
  • c
    Finally broke $1.50 which was resistance and now should become support. Bluebird has a nasty capital structure and will need a boatload of cash in the near term, even with the newly approved vouchers. CBIO is fully funded, very low overhead and in monetization mode. I am holding for a spike.
  • D
    going to 1.50+ today shorts couldnt bring this stock down despite it going up 240% the day before, easy win coming here long 1.20
  • c
    Overhead down 70%, cash $90M, perfectly set up for takeover.
  • T
    When it comes to investing,we want our money to grow with the highest rates of return,and the lowest risk possible.While there are no shortcuts to getting rich,but there are smart ways to go about it...
  • P
    Current market cap $11 million. Sale of assets $60 million. Normally the market cap exceeds the cash balance.
    Do the math...
  • t
    (ADIL) MC $25 m--Blockbuster Phase 3 data in July =$$$$$$$$$$$$$$
    "The data sets have been transferred to the Company’s independent, external statistical consultants who have initiated the analysis of the data. Adial anticipates that it will provide top-line results in July 2022."